Physician profile
Brandon E Bourgeous
NPI 1669476602
$1,745.89
in general payments reported to CMS, 2019-2025
32 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $314 · 2020: $203 · 2021: $251 · 2022: $152 · 2023: $361 · 2024: $345 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $826.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Caldera Medical, INC | $301.61 | 2023-2024 | Desara |
| Abbvie INC. | $287.26 | 2019-2025 | Lo Loestrin Fe, Liletta |
| Astellas Pharma US INC | $203.82 | 2019-2024 | Veozah |
| Exeltis, USA INC. | $86.80 | 2020-2024 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $74.67 | 2019-2022 | |
| Pfizer INC. | $69.20 | 2023-2025 | |
| Ethicon US, LLC | $56.03 | 2019-2023 | Enseal X1, Stratafix |
| Coopersurgical, INC. | $50.99 | 2023 | Paragard T 380a |
| Myovant Sciences INC. | $50.16 | 2021-2022 | |
| Octapharma USA, INC. | $48.20 | 2025 | Fibryga |
| Therapeuticsmd, INC. | $46.17 | 2021 | |
| Ironwood Pharmaceuticals, INC | $34.90 | 2019 | |
| Mayne Pharma Commercial LLC | $32.31 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $31.69 | 2019-2024 | Gardasil 9, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.13 | 2021-2023 | Trulance, Xifaxan |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $30.88 | 2022 | |
| Hologic Sales and Service, LLC | $28.51 | 2019 | |
| Novo Nordisk INC | $28.17 | 2019-2020 | |
| Amgen INC. | $28.03 | 2020-2022 | |
| Eisai INC. | $26.49 | 2020 | |
| Covidien Lp | $25.84 | 2019 | |
| Ferring Pharmaceuticals INC. | $21.49 | 2019 | |
| Axonics, INC. | $21.15 | 2024 | Axonics |
| Vertex Pharmaceuticals Incorporated | $19.08 | 2025 | |
| Biogen, INC. | $18.27 | 2025 | Zurzuvae |
| Biohaven Pharmaceuticals, INC. | $16.58 | 2021 | |
| Dysis Medical, INC. | $14.29 | 2020 | |
| Minerva Surgical, INC | $13.26 | 2022 | |
| Sumitomo Pharma America, INC. | $12.91 | 2023 | Gemtesa |
| Coloplast Corp | $12.54 | 2021 | |
| Roche Diagnostics Corporation | $12.25 | 2019 | |
| Lupin INC. | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Bourgeous listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.